Sign in

CIK 0001640266

  • Accelerated filer
  • Smaller reporting company

Voyager Therapeutics, Inc.

Sign in to watch
Ticker
VYGR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 857-259-5340
Business address
75 HAYDEN AVENUE, LEXINGTON, MA, 02421
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Open-market sale Chief Medical Officer sold 10,086 shares at $3.43 ($34,595)
  4. 4 Open-market sale President and CEO sold 10,885 shares at $3.43 ($37,336)
  5. 4 Open-market sale Chief Scientific Officer sold 3,305 shares at $4.26 ($14,079)
  6. 4 Open-market sale President and CEO sold 11,702 shares at $4.24 ($49,616)
  7. 4 Open-market sale COO & CBO sold 3,894 shares at $4.25 ($16,550)
  8. 4 Grant or award Chief Legal Officer acquired 41,500 shares (grant or award)
  9. 4 Grant or award Chief Medical Officer acquired 63,000 shares (grant or award)
  10. 4 Grant or award Chief Financial Officer acquired 51,500 shares (grant or award)
  11. 4 Open-market sale Chief Scientific Officer sold 5,413 shares at $4.45 ($24,088)
  12. 4 Open-market sale COO & CBO sold 6,950 shares at $4.45 ($30,928)
  13. 4 Open-market sale President & CEO sold 16,644 shares at $4.45 ($74,066)
  14. 4 Open-market sale Chief Legal Officer sold 4,358 shares at $4.45 ($19,393)
  15. 4 Open-market sale COO & CBO sold 3,087 shares at $5.09 ($15,713)
  16. 4 Open-market sale Chief Scientific Officer sold 1,191 shares at $5.13 ($6,110)
  17. 4 Open-market sale COO&CBO sold 6,500 shares at $5.65 ($36,725)
  18. 4 Open-market sale Chief Legal Officer sold 5,999 shares at $5.82 ($34,914)
  19. 4 Grant or award Chief Financial Officer acquired 80,000 shares (grant or award)
  20. 4 Derivatives Options or other derivatives

Page 3 of 16 · 312 filings